Thomas Lorey
Overview
Explore the profile of Thomas Lorey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1722
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goulart R, Nayar R, Lorey T, Joste N, Stoler M
Cancer Cytopathol
. 2025 Mar;
133(4):e70006.
PMID: 40055959
Because of many factors, the landscape of cervical cancer prevention is again at a pivot point within the United States. Primary human papillomavirus (HPV) screening has been recommended as the...
2.
Clarke M, Befano B, Wentzensen N, Cheung L, Egemen D, Castle P, et al.
Am J Obstet Gynecol
. 2024 Dec;
PMID: 39647654
Background: Individuals with obesity have an increased risk of cervical cancer, in part related to challenges associated with cervical sampling and visualization that result in missed detection of cervical precancers....
3.
Somatic mutations in 3929 HPV positive cervical cells associated with infection outcome and HPV type
Pinheiro M, Wentzensen N, Dean M, Yeager M, Chen Z, Shastry A, et al.
Nat Commun
. 2024 Sep;
15(1):7895.
PMID: 39266536
Invasive cervical cancers (ICC), caused by HPV infections, have a heterogeneous molecular landscape. We investigate the detection, timing, and HPV type specificity of somatic mutations in 3929 HPV-positive exfoliated cervical...
4.
Das S, Wentzensen N, Sawaya G, Egemen D, Locke A, Kinney W, et al.
J Natl Cancer Inst
. 2024 Jun;
116(9):1525-1529.
PMID: 38830048
Implementation of primary human papillomavirus (HPV) testing has been slow in the United States perhaps because of concerns of decreased sensitivity compared with concurrent HPV and cytology testing ("cotesting"). We...
5.
Befano B, Wentzensen N, Lorey T, Poitras N, Cheung L, Schiffman M, et al.
Gynecol Oncol
. 2024 Feb;
184:89-95.
PMID: 38301311
Objectives: The longer-term impact of introducing human papillomavirus (HPV) testing into routine cervical cancer screening on precancer and cancer rates by histologic type has not been well described. Calendar trends...
6.
Pierre C, Marzinke M, Ahmed S, Collister D, Colon-Franco J, Hoenig M, et al.
J Appl Lab Med
. 2023 Jun;
8(4):789-816.
PMID: 37379065
Background: Kidney disease (KD) is an important health equity issue with Black, Hispanic, and socioeconomically disadvantaged individuals experiencing a disproportionate disease burden. Prior to 2021, the commonly used estimated glomerular...
7.
Schiffman M, Mirabello L, Egemen D, Befano B, Xiao Y, Wentzensen N, et al.
Gynecol Oncol
. 2023 May;
174:253-261.
PMID: 37243996
Background: Cervical screening has not effectively controlled cervical adenocarcinoma (AC). Human papillomavirus (HPV) testing is recommended for cervical screening but the optimal management of HPV-positive individuals to prevent AC remains...
8.
Castle P, Befano B, Schiffman M, Wentzensen N, Lorey T, Poitras N, et al.
Prev Med
. 2022 Jul;
162:107157.
PMID: 35810936
As the US moves increasingly towards using human papillomavirus (HPV) testing with or without concurrent cytology for cervical cancer screening, it is unknown what the corresponding risks are following a...
9.
Cohen C, Wentzensen N, Lahrmann B, Tokugawa D, Poitras N, Bartels L, et al.
Clin Infect Dis
. 2022 Mar;
75(9):1565-1572.
PMID: 35325073
Background: Human papillomavirus-related biomarkers such as p16/Ki-67 "dual-stain" (DS) cytology have shown promising clinical performance for anal cancer screening. Here, we assessed the performance of automated evaluation of DS cytology...
10.
Demarco M, Egemen D, Hyun N, Chen X, Moscicki A, Cheung L, et al.
J Low Genit Tract Dis
. 2022 Mar;
26(2):127-134.
PMID: 35249974
Objective: The US screening and management guidelines for cervical cancer are based on the absolute risk of precancer estimated from large clinical cohorts and trials. Given the widespread transition toward...